Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | FADS1 | O60427 | 5/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31424183 | 1.00 | PTGS1 (0.68) | PTGS1HTTFADS1NPC1RAB9A | |
| SCHEMBL17744881 | 0.89 | FADS1 (0.72) | PTGS1FADS1NPC1RAB9AP2RX1 | |
| SCHEMBL9810110 | 0.84 | ALDH1A1 (0.72) | PTGS1FADS1NPC1RAB9AP2RX1 | |
| SCHEMBL22820085 | 0.83 | HTT (0.71) | HTTNPC1RAB9AHPGDTSHR | |
| SCHEMBL2700103 | 0.83 | HTT (0.71) | HTTNPC1RAB9AHPGDTSHR | |
| SCHEMBL2699846 | 0.83 | P2RX1 (0.68) | HTTFADS1NPC1RAB9AHPGD | |
| SCHEMBL5668126 | 0.83 | FADS1 (0.65) | PTGS1FADS1NPC1RAB9AP2RX1 | |
| SCHEMBL31424193 | 0.83 | MEN1 (0.72) | PTGS1FADS1NPC1RAB9AHPGD | |
| SCHEMBL259352 | 0.83 | MEN1 (0.72) | PTGS1FADS1NPC1RAB9AHPGD | |
| SCHEMBL8485797 | 0.83 | FADS1 (0.65) | PTGS1FADS1NPC1RAB9AP2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1014962-A4 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2007-06-27 | — | — | EP | disclosed |
| US-6605626-B2 | Benzamide inhibitors of factor Xa | ELI LILLY AND COMPANY | 2003-08-12 | — | — | US | disclosed |
| US-20020120007-A1 | Benzamide inhibitors of factor Xa | BEIGHT DOUGLAS WADE (US) | 2002-08-29 | — | — | US | disclosed |
| US-6313122-B1 | AS INHIBITORS OF FACTOR XA AND ARE USED AS ANTICOAGULANTS IN MAMMALS | ELI LILLY AND COMPANY | 2001-11-06 | — | — | US | disclosed |
| EP-1014962-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-1999000121-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1999-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120007-A1 | Benzamide inhibitors of factor Xa | TFPI, F11, F12 | PTGS1 1623/4885HTT 3857/4885FADS1 1832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.